Trio of therapies reduces risk of death in patients with severe COVID-19
A combination of dexamethasone, remdesivir, and baricitinib was associated with…
A combination of dexamethasone, remdesivir, and baricitinib was associated with a ‘significant survival benefit’ when compared with dual therapy of dexamethasone with remdesivir, according to a retrospective study.